Name: 4D-150 in Neovascular age-related macular degeneration: VEGF trap fusion proteins
Published: 2026-09-17T18:33:01-04:00

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

VEGF trap fusion proteins

6 evidence topics · 6 sources

Aflibercept 2 mg: VIEW 1 and VIEW 2 phase 3 trials

“Patients were randomized to intravitreal aflibercept 0.5 mg monthly (0.5q4), 2 mg monthly (2q4), 2 mg every 2 months after 3 initial monthly doses (2q8), or ranibizumab 0.5 mg monthly (Rq4).” (opens the source at this quote in a new tab)
“In a prespecified integrated analysis of the 2 studies, all aflibercept regimens were within 0.5 letters of the reference ranibizumab for mean change in BCVA; all aflibercept regimens also produced similar improvements in anatomic measures.” (opens the source at this quote in a new tab)
“These studies demonstrate that aflibercept is an effective treatment for AMD, with the every-2-month regimen offering the potential to reduce the risk from monthly intravitreal injections and the burden of monthly monitoring.” (opens the source at this quote in a new tab)

Aflibercept 2 mg: FDA-labeled dosing

“The recommended dose for EYLEA is 2 mg (0.05 mL of 40 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 12 weeks (3 months), followed by 2 mg (0.05 mL of 40 mg/mL solution) via intravitreal injection once every 8 weeks (2 months).” (opens the source at this quote in a new tab)
“Although not as effective as the recommended every 8 week dosing regimen, patients may also be treated with one dose every 12 weeks after one year of effective therapy.” (opens the source at this quote in a new tab)

Aflibercept 8 mg: PULSAR 48-week results

“PULSAR is a phase 3, randomised, three-group, double-masked, non-inferiority, 96-week trial conducted across 223 sites worldwide.” (opens the source at this quote in a new tab)
“Aflibercept 8 mg showed efficacy and safety with extended dosing intervals, which has the potential to improve the management of patients with nAMD.” (opens the source at this quote in a new tab)

Aflibercept 8 mg: PULSAR 96-week results

“Least squares (LS) mean change from baseline in BCVA at week 96 was +5.6 (95% confidence interval [Cl], 4.1-7.1), +5.5 (95% Cl, 4.0-7.0), and +6.6 (95% Cl, 5.2-8.0) letters in the 8q12, 8q16, and 2q8 groups, respectively” (opens the source at this quote in a new tab)
“Patients completing 96 weeks of treatment in the 8q12, 8q16, and 2q8 groups received a mean of 9.7, 8.2, and 12.8 active injections, respectively.” (opens the source at this quote in a new tab)
“Of these, 87% of patients in the 8q12 group had last assigned dosing intervals of 12 weeks or more, whereas 78%, 53%, and 31% of patients in the 8q16 group qualified for last assigned dosing intervals of ≥ 16 weeks, ≥ 20 weeks, and 24 weeks, respectively.” (opens the source at this quote in a new tab)

Aflibercept 8 mg: FDA-labeled dosing

“The recommended dose for EYLEA HD is 8 mg (0.07 mL of 114.3 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses, followed by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 16 weeks, +/- 1 week.” (opens the source at this quote in a new tab)

Aflibercept 2 mg biosimilars

“In 2024, the FDA approved five biosimilars to aflibercept 2 mg as of November 2024” (opens the source at this quote in a new tab)
“All are injected intravitreally as a 2-mg solution, and the adverse events appear comparable to aflibercept.” (opens the source at this quote in a new tab)